bring international expertise and reach, with clinical and clinical research experience, diagnostic test delivery and development and extensive educational experience, in fungal infections.
Matthew Burton is a Wellcome Trust Senior Research Fellow in Clinical Medicine and Professor of International Eye Health at the International Centre for Eye Health, London School of Hygiene & Tropical Medicine. He is also an Honorary Consultant Ophthalmologist in Cornea & External Eye Disease at Moorfields Eye Hospital, London, where he specializes in the diagnosis and treatment of severe corneal infections (microbial keratitis).
Matthew’s major research focus is on infectious causes of blindness, including fungal keratitis, bacterial keratitis and trachoma in sub-Saharan Africa and South Asia. He works with research collaborators in Tanzania, Kenya, Ethiopia, Uganda, The Gambia, Nepal and India. He is leading a programme of research around the development of diagnostics and treatment for microbial keratitis in low income settings. He is also the Director of the Commonwealth Eye Health Consortium, which supports training and research capacity development for eye health professionals in low and middle-income countries.
Donald Cole (Professor) trained as a physician and practised primary care, public health, occupational health and environmental health in a variety of settings in Canada and lower and middle income countries. After a Masters in Health Research Methods and a residency at McMaster, he qualified as a specialist in Occupational Medicine (1990) and Community Medicine (1992). A Tri-Council Eco-Research fellowship in environmental epidemiology led to research on environmental contaminants, ecosystems, human health and public health responses.
The role of Interim Director of Research at the Institute for Work & Health fostered research on burden of disease, health services, and evaluation of complex interventions for health. With support from the Rockefeller Foundation, CIDA, IDRC and the Bill and Melinda Gates Foundation, he has co-led research on pesticides (surveillance and health impacts), urban agriculture and nutrition in South America and East Africa. He was founding Director of the Collaborative PhD Program in Global Health at the University of Toronto and Co-Chair of the Canadian Coalition for Global Health Research’s Capacity Development Program. He currently teaches and mentors a wide range of young researchers using mixed methods. He contributes research evidence on higher education, research systems development and public health globally.
Dr. David Perlin is Executive Director of the UMDNJ/New Jersey Medical School’s Public Health Research Institute (PHRI), a 72 year old specialized center for global infectious diseases research. He is also Director of the new UMDNJ Regional Biocontainment Laboratory, one of thirteen national centers, and a Professor of Microbiology and Molecular Genetics. Dr. Perlin helped establish PHRI as a leading tuberculosis and opportunistic infections research organization. His primary expertise is in fungal infections, antifungal drug resistance and rapid diagnosis of opportunistic drug resistant pathogens in high-risk patients. His laboratory is supported by grants from the NIH, pharma and biotech sectors. He is on the editorial board of several scientific journals and serves on the Board of Directors of the Aaron Diamond AIDS Research Center and Scientific/Medical Advisory Boards for pharma and biotech companies, and PinnacleCare. He is also a member of the New York City Department of Health and Mental Hygiene Advisory Panel on Bioterrorism and Emerging Infections and the Executive Committee of the Northeast Biodefense Center.
Dr. Perlin earned an AB degree from Brandeis University in 1976 and a Ph.D. from Cornell University in 1980. He pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin joined PHRI in 1985; he was named Scientific Director in 1992, President in 2005, and Director of the new UMDNJ Center in 2006. He was appointed Professor of Microbiology and Molecular Genetics in 2003 and Executive Director of PHRI and the national Regional Biocontainment Laboratory in 2010. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005 and a Visiting Professor at the University of Manchester, UK in 2009.
Dr Arnaldo Colombo received his medical degree from the Federal University of São Paulo in 1983, and continued his residency training on Internal Medicine and Infectious Diseases there subsequently. After his residency training and master degree on Infectious Diseases he completed his fellowship training in medical mycology at the University of Texas Health Science Center at San Antonio, Texas-USA. He received his PhD degree from the UNIFESP on 1994. Dr Colombo has authored and co-authored a total 130 publications in peer-reviewed journals (H-index of 27), including original and review articles published in The N Engl J Med, Clin Infect Dis and Clin Microbiol Rev. He has organized several multicenter surveillance studies to characterize the epidemiology of emergent fungal infections in Brazil, and has actively participated in several worldwide surveillance programs to evaluate azole antifungal resistance to Candida spp. He serves as a reviewer and member of the editorial board of many medical journals, as consulting for several leading research institutions in Brazil as well as pharmaceutical companies.
He founded the Special Mycology Laboratory that is a national reference laboratory for yeast identification, typing and evaluation of antifungal resistance. He is also the coordinator of the Clinical Mycology Branch of the Brazilian Society of Infectious Diseases and has organized several guidelines for the clinical management of invasive fungal infections in Latin America. Of note, he was the Vice-Chancellor of Graduate Students and Research of the Federal University of São Paulo during the period between February-2009 and February-2012.
Dr Tania Sorrell has longstanding interests in prevention, diagnosis and treatment of Infectious Diseases, especially in immune-compromised hosts, and in the emergence of resistant microorganisms. Her research into the serious fungal infection, cryptococcosis, has provided new insights into host-microbial interactions and resulted in a new antifungal drug development program. She has developed new diagnostics for fungal diseases, led national studies of the epidemiology of invasive fungal infections and is/has been a member of international committees developing guidelines for antifungal therapy. She has served/serves on state and national advisory committees in Infectious Diseases, approval of therapeutic agents and both the Research and Human Ethics Committees of the National Health and Medical Research Council of Australia.
Dr Arunaloke Chakrabarti earned his MD in Microbiology from Postgraduate Institute of Medical Education & Research, Chandigarh, India in 1985 and is presently working as Professor In-Charge, Division of Mycology at the same Institute.
He is currently the Vice-President of International Society for Human and Animal Mycology (ISHAM), President of Society for Indian Human and Animal Mycologists (SIHAM), President of Indian Association of Medical Microbiologists, Coordinator of the ISHAM working group on ‘Fungal sinusitis’ and ‘ABPA in asthmatics’, chair of ‘Asian Fungal Working Group’, and member of two more ISHAM working groups. He is Associate Editor of ‘Medical Mycology’, and Editor/Associate Editor/Deputy Editor of three more journals – Mycopathologia, Journal of Medical Microbiology, Mycoses.
He has published >170 papers in the field of Medical Mycology and delivered lectures in >100 medical conferences and societies. He wrote chapters in 11 books. His major contribution is in the field of epidemiology of fungal sinusitis, mucormycosis, and hospital acquired fungal infections. His laboratory identified the endemic regions of fungal sinusitis, sporotrichosis, penicilliosis, source of Cryptococcus gattii in India, emergence of Apophysomyces elegans in tropical countries. His laboratory investigated many nosocomial fungal outbreaks in developing countries, and developed molecular identification and typing methods of zygomycetes. He received multiple awards from National Societies, Academies of India, and was awarded the Fellow of National Academy of Medical Sciences and Fellow of The National Academy of Sciences, India.
He has consistently helped in the development of the discipline of Medical Mycology and laboratories in India. He conducts two training courses on medical mycology every year at his center. His laboratory is now recognized as ‘Center of Advanced Research in Medical Mycology’ in India, ‘WHO Collaborating Center for Reference and Research on Fungi of Medical Importance’. Recently ‘National Culture Collection of Pathogenic Fungi’ has been added to his laboratory.
Tom’s initial research training was in the laboratory of Professor Stuart Levitz in Boston, where he worked on immune responses to Cryptococcus neoformans, a common cause of meningitis in immunocompromised patients, especially those infected with HIV. His clinical research training was through the programmes in Clinical Effectiveness and International Health at Harvard Medical School. On returning to the UK, clinical trial work was developed first in Thailand, and subsequently in Africa. In the first study of its kind, by measuring the rate of clearance of infection from the cerebrospinal fluid, the fungicidal activities of different drug treatments for cryptococcal meningitis were directly compared. The technique was shown to be much more powerful than prior markers of response, opening the way for more rapid assessment of novel treatments. Follow up trials have been completed in Cape Town, Uganda and Malawi; and he heads a large phase III trial recently funded by the UK Medical Research Council. Associated laboratory projects are examining the effects of other pathogen and host factors on the outcome of infection. The feasibility of preventing of cryptococcal meningitis through screening for sub-clinical infection and pre-emptive therapy has been demonstrated, and a novel point-of-care test for immunodiagnosis developed with collaborators to aid screening. With colleagues in the InterTB Group at St George’s Hospital, Tom lead phase II and III trials of chemotherapy for tuberculosis including novel methods for rapid and reliable testing for drug sensitivity of tuberculosis isolates are being developed.
Dr Tom Harrison is an expert panel member for cryptococcal guidelines for the World Health Organisation, the Infectious Diseases Society of America and the Southern African HIV Clinicians Society and a member of the MRC College of Experts. He is also an advisor to the Health Services and the Public Health Research Board and recipient of several awards and fellowships.
Henk den Besten is a pharmaceuticals supply chain expert. His current role is with the Partnership for Supply Chain Management, employed by John Snow International. Activities include Strategic Supply Chain and procurement support for SCMS, the PEPFAR supply chain project funded by USAID. Henk has been involved in the setting up of local supply chain solutions using existing private sector supply chains in target countries and recently worked in Tanzania and Ethiopia. He has also been involved in strategic procurement activities, including sourcing of essential drugs, meeting USG quality requirements in India, China and other countries; mapping the supply chain of active pharmaceutical ingredients (API’s) and starting material for pharmaceutical products, in China, India, Korea and other countries.
He has undertaken missions for the World Health Organization, Ministry of Foreign Affairs in The Netherlands, World Bank, Danida, The Global Fund and others. From 1980 – 2005, Henk was Managing Director of IDA Foundation in the Netherlands, the world largest not for profit Essential Medicines Supplier and from 2006-2011 Managing Director of i+Solutions, a consultancy firm aimed at improving access to quality health care services in low and middle income countries, with partners including USAID, WHO/AMDS the Ecumenical Pharmaceutical Network, Johnson & Johnson, Novartis, Unitaid, The Global Fund for AIDS, TB and Malaria, MIT Zaragoza, O3i and RBM.
Juan Luis Rodríguez Tudela MD PhD was born in Madrid in 1958. He gained his MD from Complutense University of Madrid. He is a Specialist in Clinical Microbiology and studied for his PhD at the Autonomous University de Madrid.
Juan Luis was the founder of the medical Mycology Reference Laboratory of Spain at the National Centre for Microbiology of Instituto de Salud Carlos III. He served as Director National Centre for Microbiology of Instituto de Salud Carlos III from 2000 to 2003. His last position at National Centre for Microbiology of Instituto de Salud Carlos III was as Director of the Department of Bacteriology, Mycology and Parasitology. He has run a variety of research projects and scientific activities focused on fungal infections afflicting humans, early diagnosis of invasive fungal infections, standardization of antifungal susceptibility testing, resistance mechanisms, and taxonomy of fungal species.
Juan Luis has published over 230 original articles
Juan Luis has served as member of several international associations, ex-Chairman of the Steering Committee of the Antifungal Subcommittee of Antifungal Susceptibility Testing of the European Committee of Antimicrobial Susceptibility Testing (AFST-EUCAST) and advisor of the PAHO on the Antifungal Resistance Surveillance Network in Latin-America. He or members of its laboratory have run several workshops focused in diagnosis and resistance detection of fungi in different countries of American continent as Argentina, Brazil, Chile, Colombia, Cuba, and Mexico.
Dr Malcolm Richardson is the Director of the Mycology Reference Centre at the University Hospital of South Manchester and an Honorary Professor of Medical Mycology at the University of Manchester.
He is an elected Fellow of the Royal College of Pathologists and of the Society of Biology. His clinical and laboratory investigations over the past 40 years have focused on the pathogenicity, diagnosis and epidemiology of superficial and systemic fungal infections. Major funding streams have included the European Union 5th Framework Programme Co-Operative Award and the Medical Research Council.
He has published 400 original articles, book chapters and reviews and is the author or editor of fifteen mycological textbooks and handbooks, including Fungal Infection: Diagnosis and Management, 4th Edition (2012), The Pocket Guide to Fungal infection, 3rd Edition (2011), andTherapeutic Guidelines in Systemic Fungal Infection, 4th Edition (2007). Malcolm Richardson is a frequent speaker and session chair at major international conferences in the fields of clinical microbiology, infectious diseases, and medical mycology. His professional duties have included being the Editor-in-Chief of Critical Reviews in Microbiology (2008 to 2014), a member of the European Food Safety Authority’s Working Group on the Qualified Presumption of Safety of Yeasts, a WHO Working Group on Dampness and Mould, and the management group of the UK Clinical Mycology Network. Malcolm Richardson has been actively supporting the International Society for Human and Animal Mycology (ISHAM) in the capacity of General Secretary, Vice-President and President (2015-2018).